5 April 2018 - - US-based cancer care-focused company Puma biotechnology, Inc.'s (NASDAQ: PBYI) Nerlynx (neratinib) has been included as a recommended treatment option in the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology Central Nervous System Cancers for breast cancer patients with brain metastases,.
The NCCN designated Nerlynx in combination with capecitabine as a category 2A treatment option and Nerlynx in combination with paclitaxel as a category 2B treatment option.
Use, as designated for breast cancer patients with brain metastases, is outside the FDA approved indication for Nerlynx and considered investigational.
NCCN, a not-for-profit alliance of 27 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Puma biotechnology is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care.